## Non-natural myristate analogues: Synthesis and their potent, selective activity upon bloodstream Trypanosoma brucei



### INTRODUCTION

Inadequate and antiqued drugs for treating sleeping sickness, a neglected tropical disease caused by the protozoan Trypanosoma brucei (T. brucei), remains a persistent problem across many developing countries.

One chemotherapeutic target, the N-myristoyltransferase (NMT) has received significant attention in recent years and has been validated as drug target against T. brucei; ablating the NMT gene led to cell death and is thus essential for parasite survival. NMT is responsible for the attachment of myristate from myristoyl-CoA to the N-terminal glycine residue of specific proteins. Myristoylation is also required for the remodelling and exchange steps in their essential glycosylphosphatidylinositol (GPI) anchor biosynthesis.<sup>2,3</sup>

By synthesizing trypanocidal myristate analogues, it is hoped that these structural mimics will be taken up and utilized by T. brucei, leading to the interference and disruption of their essential downstream metabolic pathways.





The synthesis of myristate analogues with an EC<sub>50</sub> value (10 % foetal bovine serum) ≤30 µM is shown below. Most analogues were synthesized via and base catalyzed S<sub>N</sub>2 reaction except for C11-G which was synthesized via an EDC/HOBt coupling reaction.



# **Rachel Humann**

Supervisor: Prof. Terry Smith

School of Chemistry, BSRC, University of St Andrews, North Haugh, St Andrews, Fife, Scotland, UK

All compounds aside from EXP6 showed significantly lower EC<sub>50</sub> values in lower FBS environments. All compounds also showed a pleasing selectivity towards *T. brucei* with all EC<sub>50</sub> values being >50 times greater for the comparative experiments on

T. brucei	BSF <i>T. brucei</i>				Methylated
0 % FBS)	(5 % FBS)	PCF <i>T. brucei</i>	L. Major	HeLa EC <sub>50</sub>	analogue BSF T.
		EC <sub>50</sub> / μΜ	EC₅₀ / μM	/ μM	<i>brucei</i> (5 % FBS)
ς250 / μινι	ΕС <sub>50</sub> / μινι				EC <sub>50</sub> / μΜ
14 + 0 42	$1.00 \pm 0.12$	> 250	16.40 ±	>250	2 25 + 0 27
+4 ± 0.45	1.09 ± 0.15	~ 250	0.90	~230	2.35 ± 0.27
73 ± 1.84	5.10 ± 1.38	230.16 ±	84.21 ±	>250	67.93 ± 8.84
		62.35	5.88		
33 ± 0.98	21.65 ± 1.59	>250	31.06 ±	>250	50.52 ± 16.85
			2.48		
22 ± 1.49	4.64 ± 0.47	>250	39.83	>250	16.00 ± 1.24
			±1.22		
06 ± 0.67	8.21 ± 0.65	36.15 ± 2.27	134.39 ±	>250	>250
			8.38		
	0.45 1.0.02		48.28 ±	. 50	
36 ± 0.28	$0.45 \pm 0.03$	57.25 ± 4.76	9.78	>50	4.09 ± 0.22
95 ± 2.33	7.11 ± 0.40	>250	213.50 ±	>250	48.13 ± 7.93
			33.57		





To determine precisely which lipid species have changed, the next step is to analyze fragmentation patterns from the lipid mass spectra. This will also identify if and where my compounds are being incorporated into fatty acid chains.

myristate.

Another topic of interest is the synthesis of a bifunctional fatty acid, which incorporated a terminal alkyne and a diazirine group. The synthesis of this will allow us to further understand the targets of these myristate analogues. While the synthesis is on-going, low yielding or unsuccessful reactions requires further research to optimize such reactions.

<sup>3</sup>H labelled myristate experiments may also help to quantify the amount of myristate analogues being taken up/ how much they block the uptake of <sup>3</sup>H labelled

		9 % O
	29 %	0 12 % 0 TMS



**References**:

1. https://www.yourgenome.org/facts/what-is-african-sleeping-sickness (accessed June 2021) 2. T. Bayliss et al., J. Med. Chem., 2017, 60, 9790-9806 3. Y. Hong, T. Kinoshita, Korean J. Parasitol., 2009, 47 (3), 197-204 4. https://commons.wikimedia.org/wiki/File:Trypanosome\_Cell\_Structure.png (accessed June 2021)